Department of Urology, The First Affiliated Hospital of Harbin Medical University, Harbin, Heilongjiang, China.
Medicine (Baltimore). 2022 Aug 5;101(31):e29561. doi: 10.1097/MD.0000000000029561.
Renal cell carcinoma (RCC) is a malignant tumor of urinary system, and clear cell RCC (ccRCC) is the major pathological subtype. A high-frequency mutation in SETD2 gene is related to the occurrence, development, and poor prognosis of RCC.
The research of immune-related genes (IRGs) is important to the success of immunotherapy in RCC. The aim of this study was to develop SETD2-related immune prognostic signature (IPS) potentially useful in the prognosis prediction of ccRCC.
The expression profile, mutation profile, and clinical data related to ccRCC were obtained from the TCGA (Cancer Genome Atlas) and cBioPortal databases. The data of IRGs were downloaded from the ImmPort database.
An IPS with 5 genes (PDIA2, PAEP, AMELX, GREM2, and INHA) was constructed by analyzing the correlation between prognosis data and IRGs associated with ccRCC patients with wild type and mutant SETD2 genes. The clinical utility of the IPS and its relationship with immune microenvironment were also studied.
According to the results of this study, the IPS can be a promising biomarker of ccRCC to guide its prognosis and treatment.
肾细胞癌（RCC）是一种泌尿系统恶性肿瘤，其中透明细胞 RCC（ccRCC）是主要的病理亚型。SETD2 基因的高频突变与 RCC 的发生、发展和不良预后有关。
免疫相关基因（IRGs）的研究对于 RCC 免疫治疗的成功至关重要。本研究旨在构建 SETD2 相关免疫预后特征（IPS），以潜在地预测 ccRCC 的预后。
从 TCGA（癌症基因组图谱）和 cBioPortal 数据库中获取 ccRCC 的表达谱、突变谱和临床数据。从 ImmPort 数据库中下载 IRGs 数据。
通过分析与野生型和突变型 SETD2 基因相关的 ccRCC 患者的预后数据与 IRGs 之间的相关性，构建了一个包含 5 个基因（PDIA2、PAEP、AMELX、GREM2 和 INHA）的 IPS。还研究了 IPS 的临床实用性及其与免疫微环境的关系。
根据本研究的结果，该 IPS 可能成为 ccRCC 的一种有前途的预后生物标志物，可用于指导其预后和治疗。
